Immunotherapy for pancreatic cancer: More than just a gut feeling

Cancer Discovery

Volumn 8, Issue 4, 2018, Pages 386-388

  Riquelme, Erick ^a   Maitra, Anirban ^a   McAllister, Florencia ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GEMCITABINE; PATTERN RECOGNITION RECEPTOR;

ABLATION THERAPY; ARTICLE; CANCER GROWTH; DISEASE RESISTANCE; GAMMAPROTEOBACTERIA; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOSURVEILLANCE; IMMUNOTHERAPY; MICROBIOME; NEXT GENERATION SEQUENCING; NONHUMAN; PANCREAS CANCER; T LYMPHOCYTE ACTIVATION; TREATMENT RESPONSE; TUMOR ASSOCIATED LEUKOCYTE; TUMOR MICROENVIRONMENT; ANIMAL; CELL TRANSFORMATION; IMMUNOLOGY; MICROFLORA; MOUSE; PANCREAS TUMOR;

ANIMALS; CELL TRANSFORMATION, NEOPLASTIC; IMMUNOTHERAPY; MICE; MICROBIOTA; PANCREATIC NEOPLASMS; TUMOR MICROENVIRONMENT;

EID: 85047865846     PISSN: 21598274     EISSN: 21598290     Source Type: Journal    
DOI: 10.1158/2159-8290.CD-18-0123     Document Type: Article

References (11)

1. Housseau F, Sears CL. Enterotoxigenic bacteroides fragilis (ETBF)- mediated colitis in Min (Apc+/-) mice: a human commensal-based murine model of colon carcinogenesis. Cell Cycle 2010;9:3-5.
2. Sears CL, Garrett WS. Microbes, microbiota, and colon cancer. Cell Host Microbe 2014;15:317-28.
3. Wu S, Rhee KJ, Albesiano E, Rabizadeh S, Wu X, Yen HR, et al. A human colonic commensal promotes colon tumorigenesis via activation of T helper type 17 T cell responses. Nat Med 2009;15:1016-22.
4. Chung L, Thiele Orberg E, Geis AL, Chan JL, Fu K, Shields CED, et al. Bacteroides fragilis toxin coordinates a pro-carcinogenic inflammatory cascade via targeting of colonic epithelial cells. Cell Host Microbe 2018;23:203-14e5.
5. Urbaniak C, Cummins J, Brackstone M, Macklaim JM, Gloor GB, Baban CK, et al. Microbiota of human breast tissue. Appl Environ Microbiol 2014;80:3007-14.
6. Geller LT, Barzily-Rokni M, Danino T, Jonas OH, Shental N, Nejman D, et al. Potential role of intratumor bacteria in mediating tumor resistance to the chemotherapeutic drug gemcitabine. Science 2017;357:1156-60.
7. Gopalakrishnan V, Spencer CN, Nezi L, Reuben A, Andrews MC, Karpinets TV, et al. Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. Science 2018;359:97-103.
8. Matson V, Fessler J, Bao R, Chongsuwat T, Zha Y, Alegre ML, et al. The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients. Science 2018;359:104-8.
9. Routy B, Le Chatelier E, Derosa L, Duong CPM, Alou MT, Daillere R, et al. Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors. Science 2018;359:91-7.
10. Viaud S, Saccheri F, Mignot G, Yamazaki T, Daillere R, Hannani D, et al. The intestinal microbiota modulates the anticancer immune effects of cyclophosphamide. Science 2013;342:971-6.
11. Pushalkar S, Hundeyin M, Daley D, Zambirinis CP, Kurz E, Mishra A., et al. The pancreatic cancer microbiome promotes oncogenesis by induction of innate and adaptive immune suppression. Cancer Discov 2018;8:403-16.